BR0215613A - Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12 - Google Patents

Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12

Info

Publication number
BR0215613A
BR0215613A BR0215613-0A BR0215613A BR0215613A BR 0215613 A BR0215613 A BR 0215613A BR 0215613 A BR0215613 A BR 0215613A BR 0215613 A BR0215613 A BR 0215613A
Authority
BR
Brazil
Prior art keywords
tetrahydrofolic acid
vitamin
tetrahydrofolic
steroids
dosage units
Prior art date
Application number
BR0215613-0A
Other languages
English (en)
Inventor
Herman Jan Tijmen Coeli Bennik
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0215613A publication Critical patent/BR0215613A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS QUE COMPREENDEM UM OU MAIS ESTERóIDES, UM OU MAIS COMPONENTES TETRAHIDROFOLATO E VITAMINA B12". A presente invenção refere-se a um kit para uso em um método contraceptivo hormonal ou em uma terapia de reposição hormonal em mamíferos do sexo feminino, o dito kit compreendendo pelo menos 1O unidades de dosagem oral que contêm pelo menos 1 <109>g de um ou mais esteróides selecionados do grupo que consiste de estrogênios e progestogênios; pelo menos 0,1 mg de um ou mais componentes tetrahidrofolato selecionados do grupo que consiste de ácido (6S)-tetrahidrofólico, de ácido 5-metil-(6S)-tetrahidrofólico, de ácido 5-formil-(6S)-tetrahidrofólico, de ácido 10-formil-(6R)-tetrahidrofólico, de ácido 5,10-metileno-(6R)-tetrahidrofólico, de ácido 5,10-metenil-(6R)-tetrahidrofólico, de ácido 5-formimino-(6S)-tetrahidrofólico, de sais farmaceuticamente aceitáveis destes ácidos tetrahidrofólicos e de derivados de glutamila destes ácidos tetrahidrofólicos e pelo menos 0,1 mg de vitamina B12. Outros aspectos da presente invenção referem-se a um método contraceptivo hormonal e a um método de terapia de reposição hormonal que compreende a administração oral de pelo menos uma vez ao dia de uma ou mais unidades de dosagem contendo esteróide a um indivíduo do sexo feminino em que as unidades de dosagem adicionalmente contêm pelo menos 0,1 mg de um ou mais dos componentes tetrahidrofolato mencionados acima e pelo menos 0,1 mg de vitamina B12.
BR0215613-0A 2002-02-21 2002-11-15 Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12 BR0215613A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075695 2002-02-21
PCT/NL2002/000741 WO2003070255A1 (en) 2002-02-21 2002-11-15 Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12

Publications (1)

Publication Number Publication Date
BR0215613A true BR0215613A (pt) 2004-12-07

Family

ID=27741182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215613-0A BR0215613A (pt) 2002-02-21 2002-11-15 Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12

Country Status (29)

Country Link
US (1) US20050164977A1 (pt)
EP (1) EP1478373B1 (pt)
JP (1) JP5037779B2 (pt)
KR (1) KR100936827B1 (pt)
CN (1) CN1620302B (pt)
AT (1) ATE341333T1 (pt)
AU (1) AU2002343249B2 (pt)
BR (1) BR0215613A (pt)
CA (1) CA2476940C (pt)
CR (1) CR7420A (pt)
CY (1) CY1106273T1 (pt)
DE (1) DE60215224T2 (pt)
DK (1) DK1478373T3 (pt)
EA (1) EA007599B1 (pt)
EC (1) ECSP045305A (pt)
ES (1) ES2274107T3 (pt)
HK (1) HK1078780A1 (pt)
HU (1) HUP0402674A3 (pt)
IL (2) IL163579A0 (pt)
ME (1) MEP37208A (pt)
MX (1) MXPA04008185A (pt)
NO (1) NO20043932L (pt)
NZ (1) NZ534806A (pt)
PL (1) PL209558B1 (pt)
PT (1) PT1478373E (pt)
RS (1) RS50909B (pt)
UA (1) UA80965C2 (pt)
WO (1) WO2003070255A1 (pt)
ZA (1) ZA200407545B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012227235B2 (en) * 2005-05-13 2015-06-11 Bayer Intellectual Property Gmbh Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
DE102005023301B4 (de) * 2005-05-13 2012-05-31 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
US20060293295A1 (en) * 2005-05-13 2006-12-28 Kai Strothmann Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
AU2013202756B2 (en) * 2006-07-06 2015-06-04 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
GB0715502D0 (en) * 2007-08-08 2007-09-19 Univ Manchester Methods
US20110097405A1 (en) * 2008-02-13 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2324832B2 (de) * 2009-11-09 2016-11-30 Biogena Naturprodukte GmbH & Co KG Nahrungsergänzungsmittel bei Einnahme von hormonellen Kontrazeptiva
MX341561B (es) 2011-06-01 2016-08-25 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10357496B2 (en) * 2011-11-05 2019-07-23 South Alabama Medical Science Foundation Methods, formulations, and kits for rapidly repleting folate levels in women
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3079671B1 (en) * 2013-12-12 2017-10-25 Donesta Bioscience B.V. Orally disintegrating solid dosage unit containing an estetrol component
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然の併用ホルモン補充療法剤及び療法
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
NO3106148T3 (pt) 2015-06-18 2018-08-11
WO2016203009A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243981C (en) * 1996-01-31 2005-09-06 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
CA2261764A1 (en) * 1996-07-30 1998-02-05 Jeffrey B. Blumberg Dietary supplements
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
US6220453B1 (en) * 1998-04-07 2001-04-24 Fuji Photo Film Co., Ltd. Blood filter unit
TR200002995T2 (tr) * 1998-04-17 2001-01-22 Ortho-Mcneil Pharmaceutical,Inc. Folik asit ihtiva eden farmasötik bileşimler, bununla ilgili yöntemler ve uygulama sistemleri
AU4573899A (en) * 1998-06-19 2000-01-05 Beth Israel Deaconess Medical Center Dietary supplement for post-menopausal women
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) * 2000-10-24 2002-04-30 Иван ХРИСТОВ Medicamentous preparation for multiple sclerosis treatment

Also Published As

Publication number Publication date
HUP0402674A2 (hu) 2005-04-28
CA2476940A1 (en) 2003-08-28
KR20040094711A (ko) 2004-11-10
CN1620302A (zh) 2005-05-25
KR100936827B1 (ko) 2010-01-14
HUP0402674A3 (en) 2012-12-28
EA007599B1 (ru) 2006-12-29
US20050164977A1 (en) 2005-07-28
IL163579A0 (en) 2005-12-18
ECSP045305A (es) 2004-10-26
EP1478373A1 (en) 2004-11-24
CY1106273T1 (el) 2011-10-12
PL209558B1 (pl) 2011-09-30
MEP37208A (en) 2011-02-10
AU2002343249A1 (en) 2003-09-09
EA200401014A1 (ru) 2006-10-27
JP2005523283A (ja) 2005-08-04
EP1478373B1 (en) 2006-10-04
RS73304A (en) 2007-02-05
HK1078780A1 (en) 2006-03-24
NZ534806A (en) 2006-05-26
DK1478373T3 (da) 2007-01-15
DE60215224D1 (de) 2006-11-16
MXPA04008185A (es) 2004-11-26
PT1478373E (pt) 2007-01-31
CA2476940C (en) 2011-11-01
NO20043932L (no) 2004-11-19
JP5037779B2 (ja) 2012-10-03
ATE341333T1 (de) 2006-10-15
CN1620302B (zh) 2011-04-27
WO2003070255A1 (en) 2003-08-28
ES2274107T3 (es) 2007-05-16
PL371441A1 (en) 2005-06-13
CR7420A (es) 2006-02-06
RS50909B (sr) 2010-08-31
AU2002343249B2 (en) 2009-02-05
ZA200407545B (en) 2006-06-28
IL163579A (en) 2011-03-31
UA80965C2 (en) 2007-11-26
DE60215224T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
BR0215613A (pt) Composições farmacêuticas que compreendem um ou mais esteróides, um ou mais componentes tetrahidrofolato e vitamina b12
AU739544B2 (en) The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
JP2008520574A5 (pt)
EA028530B1 (ru) Способ получения лекарственного средства, используемого в качестве контрацептива и предотвращающего заболевания и пороки развития, вызванные недостатком фолата, при этом не скрывая симтома недостатка витамина в
EP2037935A1 (de) Pharmazeutische zubereitung zur kontrazeption und zur verminderung des risikos angeborener fehlbildungen
JP2009514776A5 (pt)
AU2001297789B9 (en) Compositions and methods for treating an arthritic condition
AU2001297789A1 (en) Compositions and methods for treating an arthritic condition
TH105386A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยโปรเจสโตเจน และ/หรือ เอสโตรเจน และ 5-เมธิล-(6s)-เททระไฮโดรโฟเลต
EP1891959A1 (de) Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: ALTERADO DE: SCHERING AKTIENGESELLSCHAFT

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/714, 31/70; A61P 15/12, 15/18, 15/00

Ipc: A61K 31/714 (2011.01), A61K 31/70 (2011.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2280 DE 16/09/2014